For ovarian (OC) and head and neck squamous cell carcinoma (HNSCC), this was half of all cases with MYC amplifications, while in breast cancer (BC) this was ∼90% cases (Supplementary Figure 1B). This evidence concerns the gene MYC and breast cancer.